Feasibility and Safety of a Combined Metabolic Strategy in Glioblastoma Multiforme: A Prospective Case Series
Table 3
Metabolic data for the combined metabolic strategy.
Metabolic data
Patients (n = 10)
Time
Time from diagnosis to commencing combined metabolic strategy (days)
151 +/–128
Time spent undergoing combined metabolic strategy (days)
161 +/–74
Time spent fasting (days)
34 +/–18
Time spent on ketogenic diet (days)
127 +/–59
Number of fasts per patient
5.7 +/–2.7
Length of fasts (days)
6.0 +/–1.4
Blood glucose and ketones (fasts and ketogenic diet combined)
Blood glucose (mmol/L)
5.44 +/–0.55
Blood ketones (mmol/L)
1.69 +/–0.62
Proportion of patients achieving a glucose ketone index <6
9 (90%)
Mean glucose ketone index, all patients
3.22
Blood glucose and ketones (fasts)
Blood glucose (mmol/L)
4.50 +/–0.68
Blood ketones (mmol/L)
3.52 +/–0.99
Mean glucose ketone index, all patients
1.28
Blood glucose and ketones (ketogenic diet)
Blood glucose (mmol/L)
5.66 +/–0.46
Blood ketones (mmol/L)
1.11 +/–0.52
Mean glucose ketone index, all patients
5.10
Change in body weight
Change in body weight during combined metabolic strategy (kg)
−8.4 +/–6.9
Change in body weight (%)
−11.2%
Change in body mass index during combined metabolic strategy (kg/m2)
−2.9 +/–2.3
Change in body mass index (%)
−11.2%
The date of biopsy was taken as the date of diagnosis, except for the patient whose tumour could not be biopsied, in whom the date of the initial MRI scan was taken as the date of diagnosis. Except for indices and % values, values are presented as mean +/–standard deviation.
